Krishna Veeraraghavan

You have the large pharmaceutical companies which have these patent cliffs coming off. They're going to lose exclusivity and they need to fill that pipeline... they have an exceeding amount of financial ability and capital to do that. Big Pharma is facing an existential revenue threat as blockbuster drugs lose patent protection. Armed with massive cash reserves, they will be forced to aggressively acquire small and mid-cap biotech companies—specifically in oncology, immunology, and cardiometabolic spaces—to buy innovation, driving up valuations across the entire biotech sector. LONG. A target-rich environment combined with desperate, cash-rich buyers will create significant buyout premiums for innovative biotech firms. Increased FTC antitrust scrutiny could chill mega-mergers, or high-profile clinical trial failures could reduce the pool of viable acquisition targets.

You have the large pharmaceutical companies which have these patent cliffs coming off. They're going to lose exclusivity and they need to fill that pipeline... they have an exceeding amount of financial ability and capital to do that. Big Pharma is facing an existential revenue threat as blockbuster drugs lose patent protection. Armed with massive cash reserves, they will be forced to aggressively acquire small and mid-cap biotech companies—specifically in oncology, immunology, and cardiometabolic spaces—to buy innovation, driving up valuations across the entire biotech sector. LONG. A target-rich environment combined with desperate, cash-rich buyers will create significant buyout premiums for innovative biotech firms. Increased FTC antitrust scrutiny could chill mega-mergers, or high-profile clinical trial failures could reduce the pool of viable acquisition targets.